Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Warfarin Prophylaxis for Anterior Infarction: Another Black Mark for Triple Therapy.

Cardiovascular revascularization medicine : including molecular interventions·2017
Same author

Comparison of Baseline Characteristics and Inhospital Outcomes of Patients and Use of Bare Metal Versus Drug-Eluting Stents During Percutaneous Coronary Intervention 2005 to 2015 at a Single Tertiary Hospital.

The American journal of cardiology·2017
Same author

Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.

The American journal of cardiology·2017
Same author

Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry).

Cardiovascular revascularization medicine : including molecular interventions·2016
Same author

Comparison of transradial and transfemoral access in patients undergoing percutaneous coronary intervention for complex coronary lesions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2016
Same author

Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.

Cardiovascular revascularization medicine : including molecular interventions·2016

Related Experiment Videos

Proton pump inhibitors and clopidogrel.

Michael A Gaglia1, Ron Waksman

  • 1Washington Hospital Center, Washington, DC 20010, USA.

Cardiovascular Therapeutics
|March 30, 2010
PubMed
Summary

Proton pump inhibitors may reduce clopidogrel effectiveness by inhibiting its metabolism. This drug interaction can increase the risk of cardiovascular events in patients taking both medications.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Proton pump inhibitors (PPIs) are frequently co-prescribed with clopidogrel to prevent gastrointestinal bleeding.
  • Emerging evidence indicates a potential link between concurrent use of PPIs and clopidogrel and increased adverse cardiovascular events.

Purpose of the Study:

  • To review the pharmacodynamic and clinical evidence regarding the interaction between proton pump inhibitors and clopidogrel.
  • To investigate whether proton pump inhibitors inhibit the metabolic activation of clopidogrel.

Main Methods:

  • Review of existing pharmacodynamic studies.
  • Analysis of clinical data on cardiovascular event rates.
  • Examination of cytochrome P450 metabolic pathways.

Main Results:

Related Experiment Videos

  • Proton pump inhibitors and clopidogrel share common metabolic pathways via the cytochrome P450 system.
  • Inhibition of clopidogrel metabolism by proton pump inhibitors may reduce the formation of its active metabolite.
  • Studies suggest higher rates of cardiovascular events in patients using both drugs compared to clopidogrel alone.

Conclusions:

  • A potential drug interaction exists between proton pump inhibitors and clopidogrel.
  • This interaction may compromise clopidogrel's antiplatelet efficacy, potentially increasing cardiovascular risk.